CervoMed Inc. Liabilities, Fair Value Adjustment
CervoMed Inc. (CRVO) reported Liabilities, Fair Value Adjustment of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-17.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:LiabilitiesFairValueAdjustment · last filed 2025-03-17
- CervoMed Inc. liabilities, fair value adjustment for the quarter ending 2024-12-31 was $0.00.
- CervoMed Inc. liabilities, fair value adjustment for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- CervoMed Inc. liabilities, fair value adjustment for the quarter ending 2024-06-30 was $0.00.
- CervoMed Inc. liabilities, fair value adjustment for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- CervoMed Inc. liabilities, fair value adjustment for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- CervoMed Inc. liabilities, fair value adjustment for fiscal 2023 was $5.42M.
- CervoMed Inc. liabilities, fair value adjustment for fiscal 2022 was -$2.39M.
| Period end | Liabilities, Fair Value Adjustment 3 month | Liabilities, Fair Value Adjustment 6 month | Liabilities, Fair Value Adjustment 9 month | Liabilities, Fair Value Adjustment 9 month as first filed | Liabilities, Fair Value Adjustment 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $0.00 derived: sum of 2 quarters · filed 2025-03-17 | $0.00 derived: sum of 3 quarters · filed 2025-03-17 | $0.00 10-K · filed 2025-03-17 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-03-17 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | $0.00 derived: sum of 3 quarters · filed 2025-03-17 | $4.78M derived: sum of 4 quarters · filed 2025-03-17 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-03-17 | $4.78M derived: sum of 3 quarters · filed 2025-03-17 | $4.57M derived: sum of 4 quarters · filed 2025-03-17 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $4.78M derived: sum of 2 quarters · filed 2025-03-17 | $4.57M derived: sum of 3 quarters · filed 2025-03-17 | $5.42M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $4.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $4.57M derived: sum of 2 quarters · filed 2024-11-12 | $5.42M 10-Q · filed 2024-11-12 | -$5.42M 10-Q · filed 2023-11-13 | $1.27M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$212.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $646.00K 10-Q · filed 2024-08-09 | -$3.51M derived: sum of 3 quarters · filed 2024-08-09 | ||
| 2023-03-31 | $858.00K 10-Q · filed 2024-05-14 | -$3.30M derived: sum of 2 quarters · filed 2024-05-14 | |||
| 2022-12-31 | -$4.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$2.39M 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $1.77M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |